Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why the Eversana–Waltz Health merger could be the biggest shake-up in drug pricing since PBMs took control
Eversana merges with Waltz Health to transform pharma commercialization and drug affordability. Discover how this new model is reshaping patient access.
Can short-acting psychedelics solve the scalability problem in depression treatment?
Short-acting psychedelics like bretisilocin could reshape mental health treatment. Can they overcome the clinical bottlenecks faced by psilocybin and ketamine?
Reese Pharmaceutical rebrands to Reese Consumer Health with global expansion and OTC brand strategy shift
Reese Pharmaceutical rebrands as Reese Consumer Health, shifting from manufacturer to brand builder with global expansion and consumer-first strategy.
Can Merck’s strategy around Keytruda formulations delay the biggest patent cliff in pharma history?
Can Merck’s subcutaneous Keytruda strategy soften the 2028 patent cliff? Explore how the drugmaker is diversifying and preparing for the biggest loss of exclusivity in pharma.
Québec and Ottawa unite to fund Delpharm’s Boucherville upgrade for hospital drug security
Find out how Delpharm’s C$220M investment is transforming its Boucherville plant into Canada’s sterile injectable powerhouse.
EMA clears Curasight’s uTREAT trial—will targeted radiopharma redefine brain cancer therapy?
Curasight wins EMA approval for its first uTREAT clinical trial in glioblastoma. Find out how its theranostic strategy could change brain cancer treatment.
Can Calluna Pharma’s CAL101 finally change the game for idiopathic pulmonary fibrosis patients?
Calluna Pharma begins Phase 2 AURORA trial of CAL101 in idiopathic pulmonary fibrosis, targeting S100A4 for a novel antifibrotic approach.
Biologics race in Indian pharma: Can Glenmark’s AbbVie tie-up spark a broader innovation moment?
India’s biologics race heats up as Glenmark, Biocon, Sun Pharma, Dr. Reddy’s, and Lupin push beyond generics—see how each strategy stacks up.
Theravance completes enrollment in Phase 3 CYPRESS trial for ampreloxetine in MSA-related nOH
Theravance completes Phase 3 enrollment for ampreloxetine in MSA-related nOH. Topline data expected in Q1 2026. Could this be a rare disease breakthrough?
Coya Therapeutics gets FDA green light for Phase 2 ALS trial with COYA 302
Coya Therapeutics receives FDA clearance to initiate a Phase 2 trial of COYA 302 for ALS. Find out what this means for investors and the ALS drug pipeline.